Research
Hormonal
Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.
Clinicians may consider glucagon-like peptide-1 receptor agonists for weight management in patients with heart failure with preserved ejection fraction.
StrongSupportsmedium confidence
clinical trials data supporting the safety and efficacy of treating obesity in patients with HF is currently limited to patients with HF with preserved ejection fraction, but do confirm safety and weight loss efficacy in this patient population.
Why this rating
The claim is based on clinical trial data.
Source
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Josephine Harrington et al. · Circulation Heart Failure · 2024
reviewCited 10×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →